Tirzepatide for T2D

The short version: tirzepatide clearly lowers blood sugar and weight in trials, but the evidence base is thin on long-term safety and real-world harm, and the most important cardiovascular trial only proved it was not worse than an older drug.

The phase 3 SURPASS trials show real effects. HbA1c dropped by about 1.7 to 2.6 percentage points, weight fell by roughly 5 to 12 kg, and more people hit normal blood sugar targets than with placebo or semaglutide [1, 3]. A 2024 head-to-head trial against semaglutide found tirzepatide lowered HbA1c by 2.05% versus 1.64%, and weight by 11.2 kg versus 6.9 kg [4]. The SURMOUNT-1 extension reported a 93% reduction in progression to type 2 diabetes over 176 weeks in people with prediabetes [6]. These are surrogate endpoints, not proof you will live longer or avoid a heart attack.

The cardiovascular evidence is weaker than the marketing suggests. SURPASS-CVOT, the big 13,299-person trial, showed tirzepatide was noninferior to dulaglutide for major cardiovascular events, meaning it was not worse, not that it was better [5]. The mortality signal came from an indirect comparison against an imputed placebo, a statistical construction, not a real control group [5]. The observational cohort showing a 40% relative reduction in cardio-renal outcomes compared tirzepatide users to other GLP-1 users, and observational comparisons of this kind carry heavy selection bias [2].

The safety picture is dose-dependent and mostly gastrointestinal. Nausea hit roughly 17 to 22% of people, vomiting 6 to 10%, and about 6 to 9% stopped the drug because of side effects [3]. The 15 mg dose in the long prediabetes trial had a 12.3% discontinuation rate versus 5.9% for placebo [6]. What the evidence does not contain is long-term safety data beyond a few years, and the dedicated cardiovascular outcome trial was designed to show noninferiority, not superiority [5]. The manufacturer funded the trials, and the reviews summarizing them are narrative syntheses, not independent verification [1, 2].

My call: tirzepatide is genuinely effective for blood sugar and weight, and the short-term risk profile is tolerable for most people, but the long-term safety data does not exist and the cardiovascular claim rests on indirect comparison, not a real placebo trial. Confidence: moderate for efficacy, low for long-term safety.